Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 4, 2014, Pages 411-419

  Wolf, Myles ^a   White, Kenneth E ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autosomal dominant hypophosphatemic rickets; Chronic kidney disease; Fibroblast growth factor 23; Iron; Iron deficiency; Osteocyte; Phosphate; Rickets

Indexed keywords

FERRIC CARBOXYMALTOSE; FIBROBLAST GROWTH FACTOR 23; IRON DEXTRAN; FIBROBLAST GROWTH FACTOR; IRON; PHOSPHATE;

AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; CHRONIC KIDNEY DISEASE; CLINICAL OBSERVATION; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOCYTE; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; BLOOD; BONE; CHRONIC KIDNEY FAILURE; DEFICIENCY; FAMILIAL HYPOPHOSPHATEMIC RICKETS; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; METABOLISM; RICKETS;

BONE AND BONES; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; IRON; OSTEOCYTES; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RICKETS;

EID: 84902250298     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000447020.74593.6f     Document Type: Review

References (62)

1. ADHR-Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26:345-348.
2. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001; 98:6500-6505.
3. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004; 145:3087-3094.
4. Burnett SM, Gunawardene SC, Bringhurst FR, et al. Regulation of C-Terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21:1187-1196.
5. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91:3144-3149.
6. Perwad F, Azam N, Zhang MY, et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005; 146:5358-5364.
7. Gribaa M, Younes M, Bouyacoub Y, et al. An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab 2010; 28:111-115.
8. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60:2079-2086.
9. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143:3179-3182.
10. Bianchine JW, Stambler AA, Harrison HE. Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 1971; 7:287-295.
11. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/ osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997; 82:674-681.
12. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21:1427-1435.
13. Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78:975-980.
14. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79:1370-1378.
15. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152:640-648.
16. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
17. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432-2439.
18. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-592.
19. Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22:956-966.
20. Kendrick J, Cheung AK, Kaufman JS, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22:1913-1922.
21. Scialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014; 25:349-360.
22. Ix JH, Katz R, Kestenbaum BR, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60:200-207.
23. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545-2552.
24. Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals followup study. Clin J Am Soc Nephrol 2011; 6:2871-2878.
25. Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24:2792-2796.
26. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87:4957-4960.
27. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348:1656-1663.
28. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 2007; 22:520-526.
29. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579-581.
30. Ichikawa S, Sorenson AH, Austin AM, et al. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology 2009; 150:2543-2550.
31. Ichikawa S, Baujat G, Seyahi A, et al. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A 2010; 152A:896-903.
32. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14:385-390.
33. Larsson T, Davis SI, Garringer HJ, et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 2005; 146:3883-3891.
34. Larsson T, Yu X, Davis SI, et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005; 90:2424-2427.
35. Frishberg Y, Ito N, Rinat C, et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2007; 22:235-242.
36. Durham BH, Joseph F, Bailey LM, Fraser WD. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 2007; 44:463-466.
37. Imel EA, Peacock M, Pitukcheewanont P, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006; 91:2055-2061.
38. Econs MJ, McEnery PT, Lennon F, Speer MC. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 1997; 100:2653-2657.
39. Imel EA, Peacock M, Gray AK, et al. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011; 96:3541-3549.
40. Braithwaite V, Jarjou LM, Goldberg GR, Prentice A. Iron status and fibroblast growth factor-23 in Gambian children. Bone 2012; 50:1351-1356.
41. Braithwaite V, Jarjou LM, Goldberg GR, et al. Follow-up study of Gambian children with rickets-like bone deformities and elevated plasma FGF23: possible aetiological factors. Bone 2012; 50:218-225.
42. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 2011; 108:E1146-E1155.
43. Clinkenbeard EL, Farrow EG, Summers LJ, et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res 2014; 29:361-369.
44. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013; 28:1793-1803.
45. Gravesen E, Hofman-Bang J, Mace ML, et al. High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats. BMC Nephrol 2013; 14:281.
46. Prats M, Font R, Garcia C, et al. Effect of ferric carboxymaltose on serum phosphate and C-Terminal FGF23 levels in nondialysis chronic kidney disease patients: post-hoc analysis of a prospective study. BMC Nephrol 2013; 14:167.
47. Hryszko T, Rydzewska-Rosolowska A, Brzosko S, et al. Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial 2012; 16:146-151.
48. Takeda Y, Komaba H, Goto S, et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011; 33:421-426.
49. Deger SM, Erten Y, Pasaoglu OT, et al. The effects of iron on FGF23- mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol 2013; 17:416-423.
50. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82:737-747.
51. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17:1305-1315.
52. Hill KM, Martin BR, WastneyME, et al.Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013; 83:959-966.
53. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429-435.
54. Rhee Y, Bivi N, Farrow E, et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011; 49:636-643.
55. Christov M, Waikar SS, Pereira RC, et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 2013; 84:776-785.
56. Stubbs JR, He N, Idiculla A, et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012; 27:38-46.
57. Smith ER, Cai MM, McMahon LP, Holt SG. Biological variability of plasma intact and C-Terminal FGF23 measurements. J Clin Endocrinol Metab 2012; 97:3357-3365.
58. Isakova T, Xie H, Barchi-Chung A, et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6:2688-2695.
59. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988- 2004. Clin J Am Soc Nephrol 2009; 4:57-61.
60. Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 2012; 30:1-9.
61. Lewis J, Dwyer JP, Koury M, et al. Ferric citrate binds phosphorus, delivers iron, and reduces IV iron and erythropoietic stimulating agent use in end-stage renal disease (abstract). J Am Soc Nephrol 2013; 24:751A.
62. Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 2014; 543-552.